Vitiligo Treatment Market: Global Industry Analysis and Forecast (2022-2029) by Type, Drug Class Type, Treatment Type, Distribution Channel, End-user, and Region

The Vitiligo Treatment Market size was valued at USD 538.5 Million in 2021 and the total Vitiligo Treatment revenue is expected to grow at a CAGR of 4.72% from 2022 to 2029, reaching nearly USD 778.79 Million.

Vitiligo Treatment Market Overview:

Vitiligo is a skin disorder characterized by a patchy loss of skin pigmentation or color. Vitiligo affects millions of individuals globally. Anyone, regardless of age, gender, or ethnicity, can be affected. Vitiligo is not a life-threatening or infectious disease, but it can have an impact on self-esteem and mental health. There is currently no cure for vitiligo, however, there are treatments available. Unfortunately, vitiligo treatments do not always work, and even when they do, vitiligo can reoccur. Some bodily parts are extremely tough to cure. There is no cure for vitiligo. The objective of therapy for most patients is to prevent vitiligo from spreading and to restore color to afflicted regions of the skin. Existing therapies can assist, but they rarely cure vitiligo and make it disappear completely. As a result, the vitiligo treatment market benefits positively. There is a rising desire for innovative and creative therapies for vitiligo management. The ever-growing demand for novel vitiligo treatment alternatives, with the goal of obtaining the first regulatory clearance for vitiligo therapy, has played a role in the growing R&D activities for vitiligo treatment. Market participants are constantly focused on the development of novel vitiligo treatment options in order to increase treatment efficiency and outcomes in the patient population. This is expected to contribute to the growth of the vitiligo treatment market during the forecast period. The increased significance of attractive appearance and consciousness, as well as the increasing prevalence of vitiligo cases, are the primary drivers boosting the global vitiligo treatment market. The advancement of technology that offers medicines for treating various difficulties produced by the condition, as well as the prevalence of government investments in healthcare infrastructure, drive market growth. However, a shortage of skilled personnel is expected to limit market growth during the forecast period. Vitiligo Treatment Market To know about the Research Methodology :- Request Free Sample Report

Vitiligo Treatment Market Dynamics:

Rising prevalence of childhood vitiligo Vitiligo might appear at any age, especially in infancy and childhood. The prevalence of vitiligo in children (aged 12 years) has been estimated to be roughly one-quarter of all vitiligo sufferers. Chinese researchers found that 24.1% of vitiligo patients were children. 16% of vitiligo sufferers in Korea were children. According to two Indian studies, the prevalence is 26% in south India and 23.3% in north India. The frequency of Segmental vitiligo (SV) in youngsters is greater (17-29%) than in adults (5%). SV is more widespread in the Korean population than in other ethnic groups. Additionally, a study of Korean children found 32.5% of them to have SV. Childhood vitiligo requires special attention since it occurs before the age of 20 in 50% of cases and before the age of 10 in 25% of cases. In general, pediatric vitiligo varies from adult vitiligo in the following ways: female predominance is found, segmental appearance is more prevalent, and accompanying autoimmune or endocrine diseases are fewer. As a result, the demand for the vitiligo treatment market is expected to grow rapidly during the forecast period. High significance of aesthetic appeals and consciousness Beauty consciousness among people has increased significantly in recent years as a result of increased consumer awareness of various aesthetic treatments, rising per capita income, and the use of digital platforms. This growth is expected to significantly influence the vitiligo treatment market growth. According to the International Society of Aesthetic Plastic Surgery (ISAPS), global total non-surgical treatments increased by 27.3% between 2015 and 2019. Meanwhile, the number of minimally invasive cosmetic operations increased by roughly 200% between 2000 and 2017, according to the American Society of Plastic Surgeons (ASPS). Similarly, around 15.9 million minimally invasive cosmetic treatments were performed in 2018, representing a 2% increase over 2017. As a result, the growing geriatric population increases the demand for minimally invasive cosmetic surgeries during the forecast period. A strong R&D pipeline and favorable clinical study findings Vitiligo affects a vast number of people globally, and the growing awareness of the condition, as well as the resultant demand for modern and effective treatment alternatives, is expected to drive the vitiligo treatment market during the forecast period. There is currently no recognized treatment option for vitiligo, resulting in increased demand for vitiligo treatment alternatives in both established and emerging economies. According to the American Academy of Dermatology (AAD), an estimated 84.5 million Americans, or one in every four, have vitiligo. Additionally, there is a significant lack of effective treatment alternatives in the present vitiligo treatment options, which can frequently result in the recurrence of vitiligo in previously treated regions of the skin. These aspects, together with leading market companies' strong R&D pipelines of novel vitiligo treatment alternatives, are some of the significant factors driving the market growth. Rising number of clinical trials Research and development, as well as clinical trials, are critical for market growth and technological advancements. Extensive research and development results in the production of more effective and superior goods that help in improved patient care, hence boosting the vitiligo treatment market growth. Besides that, there are various medicines in the pipelines and in clinical trials that are likely to greatly boost market growth if they are approved by the relevant regulatory bodies. There were no drugs authorized to treat vitiligo until July 2022, with numerous clinical trials still ongoing. The FDA authorized the first-ever re-pigmentation treatment for non-segmental vitiligo, 1.5% ruxolitinib (Opzelura) cream, for patients aged 12 and above in July 2022. As a result, such efforts by manufacturers to create unique treatments are expected to strongly drive market growth throughout the forecast period, after product approval. Scarcity of trained professionals A shortage of skilled dermatologists causes a number of challenges, including inaccurate diagnosis, lengthier processing times, overworked doctors, and ineffective therapies. According to the American Academy of Dermatology (AAD), the overall number of dermatologists in the United States has declined from 19,957 in 2019 to 18,898 in 2020. As a result, the absence of such skilled specialists to quickly diagnose and treat vitiligo is constraining market growth; nevertheless, the number of dermatologists has historically grown, and the impact of the constraint is likely to be minimal on vitiligo treatment market growth during the forecast period.

Vitiligo Treatment Market Segment Analysis:

Based on Type, the non-segmental vitiligo segment held the largest share of the global vitiligo treatment market in 2021. The segment is further expected to grow at a CAGR of 4.68% and maintain its dominance by end of the forecast period. This dominance is attributed to the rise in patients diagnosed with non-segmental vitiligo across the world. When the skin color begins to fade, the most common kind of vitiligo causes skin patches to emerge all over the body. Non-segmental vitiligo is most likely present when white spots on a person's body are symmetrical rather than asymmetrical. This vitiligo affects 0.5% to 2% of the population globally, and 90% of the time it is non-segmental. However, therapies for non-segmental vitiligo might differ greatly depending on the patient's preferences and the severity of their illness. As a result, the rise in awareness about vitiligo symptoms and causes and better treatment alternatives offers lucrative growth opportunities for the segment. Based on Drug Class Type, the Corticosteroids segment is expected to offer potential growth prospects for the vitiligo treatment market during the forecast period. Thanks to the advantages of corticosteroids including anti-inflammatory characteristics, and decreased progression rate of vitiligo, consequently dermatologists prescribe corticosteroids as first-line therapy. Likewise, an increase in patients seeking treatment for vitiligo is boosting market growth throughout the forecast period. Corticosteroids are a kind of prescription drug authorized by the US Food and Drug Administration to treat inflammation. For adults and children with localized vitiligo, topical corticosteroids are routinely used as a first-line therapy. The most often used topical corticosteroids for vitiligo include hydrocortisone, clobetasol propionate, betamethasone valerate, diflucortolone valerate, triamcinolone acetonide, methylprednisolone, fluticasone, and mometasone. Vitiligo Treatment Market 1 Based on Treatment Type, with the highest revenue share of 45%, the Tropical Treatment segment dominated the global vitiligo treatment market in 2021. In contrast to the conventional oral route, topical medication administration for vitiligo offers various advantages. It avoids several difficulties of unwanted effects, bioavailability, and so forth by bypassing all main organ systems such as the GIT, liver, and kidney. The first-line treatment for localized vitiligo is a topical treatment. Currently, several topical agents are available in many forms viz. methoxsalen (solution and cream), trioxsalen (solution), corticosteroids (gel, cream, ointment, and solution), and calcineurin inhibitors (ointment and cream). Although topical medication is vital in the treatment of vitiligo, adverse effects or low effectiveness limit its value and patient compliance. Novel drug delivery techniques can play a critical role in optimizing the topical distribution of different medications by improving their epidermal localization, reducing adverse effects, and increasing efficacy. As a result, the key players have to develop innovative treatments for satisfying the demand of the patients. Based on Distribution Channel, the Drug Stores, and Retail Pharmacies segment led the global vitiligo treatment market with the highest revenue share in 2021. Drug stores and retail pharmacies offer branded and generic medications, as well as other pharmaceutical supplies, all under one roof. These pharmacies are trustworthy advice for their clients' alternative selection, informing them about the medication's negative effects, delivering low-cost generic pharmaceuticals, and much more. As a result, consumers prefer to shop through stores. However, the Online segment is expected to grow at the highest CAGR of 4.7% and dominate the market by 2029 due to the rise E-Pharmacy channels, high discounts offered by online distributors, and the rise in the trend of online shopping. Online medication shopping is the most convenient way of shopping, anytime anywhere delivery, Range of choices, Cost-efficient, Time-saving, etc. thus, it gaining popularity and is expected to benefit the segment growth. Based on End-user, the Hospital segment generated the largest revenue share in 2021 and is expected to continue this trend by 2029 in the global vitiligo treatment market. Hospitals are often the primary centers for the diagnosis, medication, and rehabilitative services of people suffering from skin illnesses like vitiligo. The hospital industry includes both public and private facilities. To treat and diagnose vitiligo illness, hospitals use medications and procedures. Likewise, the increased awareness and efficiency of medical services are expected to encourage segment growth throughout the forecast period.

Vitiligo Treatment Market Regional Insights:

The North America market dominated the global vitiligo treatment market with the highest revenue share in 2021. The region is further expected to maintain its dominance holding the highest revenue share of 36% by end of the forecast period. The well-established healthcare infrastructure in the region, strong presence of the leading competitors, rising adoption of advanced therapies equipment, and services for better care of patients are expected to be the major factors driving the vitiligo treatment market during the forecast period. The U.S. and Canada regions are expected to contribute the largest share of the North America vitiligo treatment market. The high prevalence of vitiligo in the U.S., the developing healthcare industry, the rising adoption of modern technologies, and increasing innovative surgery procedures by key players are the factors driving the U.S. market during the forecast period. According to the American Academy of Dermatology (AAD), vitiligo affects approximately one in four persons in the U.S. This enormous vitiligo patient pool, along with increasing demand for improved therapeutic approaches, is driving up demand for the vitiligo treatment market throughout the region. The expected introduction of new products into the market, along with a rising number of patients undergoing vitiligo treatment globally, is expected to boost vitiligo treatment demand throughout the forecast period. In addition, In June 2019, Incyte reported positive results from a Phase 2 study of ruxolitinib cream in patients suffering from vitiligo. Such a product launch further helps to increase market revenue during the forecast period. The Asia Pacific market is expected to grow at a significant CAGR during the forecast period, because of the large patient population. There is a substantial patient pool in emerging economies including Pakistan, India, China, and other Southeast Asian countries in the Asia Pacific suffering from vitiligo and this has resulted in the demand for better treatment alternatives for vitiligo. Childhood vitiligo is a frequent condition of pigmentation in India. In Pakistan, 0.38% of women aged 15 to 19 have vitiligo. As a result, these women suffer a range of psychological issues throughout the marriage, including wife rejection, separation, divorce, and forced single life. As a result, the region's need for vitiligo treatment is expected to increase significantly. Vitiligo Treatment Market 3 The economies in the Latin America and Middle East & Africa have opportunities for investment due to vitiligo being more significant in darker-skinned individuals. However, there are several R&D projects and rising acceptance of vitiligo therapy among healthcare professionals in the market, and the number of vitiligo patients is growing. The rising demand for improved vitiligo treatment choices is also expected to increase the European vitiligo treatment market revenue. The market in Middle East & Africa, and Latin America accounted for a comparably moderate percentage of the market in 2021.

Vitiligo Treatment Market Scope: Inquiry Before Buying

Vitiligo Treatment Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: USD 538.5 Million
Forecast Period 2022 to 2029 CAGR: 4.72 % Market Size in 2029: USD 778.79 Million
Segments Covered: by Type • Segmental Vitiligo • Non Segmental Vitiligo
by Drug Class Type • Corticosteroids • Calcineurin Inhibitor • Others
by Treatment Type • Topical Treatment • Light Therapy • Surgical Procedures • Others
by Distribution Channel • Drug Stores and Retail Pharmacies • Online Providers • Hospital Pharmacies
by End-user • Hospitals • Aesthetic Clinics • Others

Vitiligo Treatment Market, by Region

• North America o United States o Canada o Mexico • Europe o UK o France o Germany o Italy o Spain o Sweden o Austria o Rest Of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest Of APAC • Middle East and Africa o South Africa o GCC o Egypt o Nigeria o Rest Of ME&A • South America o Brazil o Argentina o Rest Of South America

Vitiligo Treatment Market Key Players

• Arcutis Biotherapeutics (California, U.S.) • Bausch Health Companies Inc. (Canada, U.S.) • Belcher Pharmaceuticals LCC. (Florida, U.S.) • Celgene Corporation (New Jersey, U.S.) • Pfizer Inc. (New York City, U.S.) • Bausch Health Companies Inc. (New Jersey, U.S.) • Baxter International Inc. (Illinois, U.S.) • STRATA Skin Sciences (Pennsylvania, U.S.) • Eli Lilly Company (Indiana, U.S.) • Clarify Medical, Inc. ((California, U.S.) • Baxter (Illinois, U.S.) • AbbVie (Illinois, U.S.) • Salix Pharmaceuticals Inc. (New Jersey, U.S.) • Bristol-Myers Squibb (New York, U.S.) • Mylan N.V. (Hertfordshire, U.K.) • Incyte Corporation (Switzerland) • Incyte Corporation (Switzerland) • Novartis AG (Switzerland) • LEO Pharma A/S (Denmark, Europe) • Mylan N.V., (Hertfordshire, U.K.) • Astellas Pharma Inc. (Tokyo, Japan) • clinuvel pharmaceuticals ltd. (Victoria, Australia) • Dr. Reddy’s Laboratories Ltd. (India) • Glenmark Pharmaceuticals Ltd. (India) • Panacea Biotec Ltd. (India) • Strides Pharma (India) • Science Limited (Japan) • Astellas Pharma Inc. (Tokyo, Japan) • Aurobindo Pharma Ltd. (India) • Teva Pharmaceutical Industries Ltd. (Israel) FAQs: 1. What is the major growth driver for the Vitiligo Treatment market? Ans. The increased significance of attractive appearance and consciousness, as well as the increasing prevalence of vitiligo cases, are the primary drivers boosting the global vitiligo treatment market. 2. What is the major restraint for the Vitiligo Treatment market growth? Ans. The scarcity of skilled professionals are expected to be the major restraining factor for the Vitiligo Treatment market growth. 3. Which region is expected to lead the global Vitiligo Treatment market during the forecast period? Ans. The North America market is expected to lead the global Vitiligo Treatment market during the forecast period due to the well-established healthcare infrastructure in the region, strong presence of the leading competitors, rising adoption of advanced therapies equipment, and services for better care of patients. 4. What is the projected market size & growth rate of the Vitiligo Treatment Market? Ans. The Vitiligo Treatment Market size was valued at USD 538.5 Million in 2021 and the total Vitiligo Treatment revenue is expected to grow at a CAGR of 4.72% from 2022 to 2029, reaching nearly USD 778.79 Million. 5. What segments are covered in the Vitiligo Treatment Market report? Ans. The segments covered in the Vitiligo Treatment market report are Type, Drug Class Type, Treatment Type, Distribution Channel, End-user, and Region.
1. Global Vitiligo Treatment Market: Research Methodology 2. Global Vitiligo Treatment Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Vitiligo Treatment Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Vitiligo Treatment Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Vitiligo Treatment Market Segmentation 4.1 Global Vitiligo Treatment Market, by Type (2021-2029) • Segmental Vitiligo • Non Segmental Vitiligo 4.2 Global Vitiligo Treatment Market, by Drug Class Type (2021-2029) • Corticosteroids • Calcineurin Inhibitor • Others 4.3 Global Vitiligo Treatment Market, by Treatment Type (2021-2029) • Topical Treatment • Light Therapy • Surgical Procedures • Others 4.4 Global Vitiligo Treatment Market, by Distribution Channel (2021-2029) • Drug Stores and Retail Pharmacies • Online Providers • Hospital Pharmacies 4.5 Global Vitiligo Treatment Market, by End-user (2021-2029) • Hospitals • Aesthetic Clinics • Others 5. North America Vitiligo Treatment Market(2021-2029) 5.1 North America Vitiligo Treatment Market, by Type (2021-2029) • Segmental Vitiligo • Non Segmental Vitiligo 5.2 North America Vitiligo Treatment Market, by Drug Class Type (2021-2029) • Corticosteroids • Calcineurin Inhibitor • Others 5.3 North America Vitiligo Treatment Market, by Treatment Type (2021-2029) • Topical Treatment • Light Therapy • Surgical Procedures • Others 5.4 North America Vitiligo Treatment Market, by Distribution Channel (2021-2029) • Drug Stores and Retail Pharmacies • Online Providers • Hospital Pharmacies 5.5 North America Vitiligo Treatment Market, by End-user (2021-2029) • Hospitals • Aesthetic Clinics • Others 5.6 North America Vitiligo Treatment Market, by Country (2021-2029) • United States • Canada • Mexico 6. Europe Vitiligo Treatment Market (2021-2029) 6.1. European Vitiligo Treatment Market, by Type (2021-2029) 6.2. European Vitiligo Treatment Market, by Drug Class Type (2021-2029) 6.3. European Vitiligo Treatment Market, by Treatment Type (2021-2029) 6.4. European Vitiligo Treatment Market, by Distribution Channel (2021-2029) 6.5. European Vitiligo Treatment Market, by End-user (2021-2029) 6.6. European Vitiligo Treatment Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Vitiligo Treatment Market (2021-2029) 7.1. Asia Pacific Vitiligo Treatment Market, by Type (2021-2029) 7.2. Asia Pacific Vitiligo Treatment Market, by Drug Class Type (2021-2029) 7.3. Asia Pacific Vitiligo Treatment Market, by Treatment Type (2021-2029) 7.4. Asia Pacific Vitiligo Treatment Market, by Distribution Channel (2021-2029) 7.5. Asia Pacific Vitiligo Treatment Market, by End-user (2021-2029) 7.6. Asia Pacific Vitiligo Treatment Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Vitiligo Treatment Market (2021-2029) 8.1 Middle East and Africa Vitiligo Treatment Market, by Type (2021-2029) 8.2. Middle East and Africa Vitiligo Treatment Market, by Drug Class Type (2021-2029) 8.3. Middle East and Africa Vitiligo Treatment Market, by Treatment Type (2021-2029) 8.4. Middle East and Africa Vitiligo Treatment Market, by Distribution Channel (2021-2029) 8.5. Middle East and Africa Vitiligo Treatment Market, by End-user (2021-2029) 8.6. Middle East and Africa Vitiligo Treatment Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Vitiligo Treatment Market (2021-2029) 9.1. South America Vitiligo Treatment Market, by Type (2021-2029) 9.2. South America Vitiligo Treatment Market, by Drug Class Type (2021-2029) 9.3. South America Vitiligo Treatment Market, by Treatment Type (2021-2029) 9.4. South America Vitiligo Treatment Market, by Distribution Channel (2021-2029) 9.5. South America Vitiligo Treatment Market, by End-user (2021-2029) 9.6. South America Vitiligo Treatment Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Arcutis Biotherapeutics (California, U.S.) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Bausch Health Companies Inc. (Canada, U.S.) 10.3 Belcher Pharmaceuticals LCC. (Florida, U.S.) 10.4 Celgene Corporation (New Jersey, U.S.) 10.5 Pfizer Inc. (New York City, U.S.) 10.6 Bausch Health Companies Inc. (New Jersey, U.S.) 10.7 Baxter International Inc. (Illinois, U.S.) 10.8 STRATA Skin Sciences (Pennsylvania, U.S.) 10.9 Eli Lilly Company (Indiana, U.S.) 10.10 Clarify Medical, Inc. ((California, U.S.) 10.11 Baxter (Illinois, U.S.) 10.12 AbbVie (Illinois, U.S.) 10.13 Salix Pharmaceuticals Inc. (New Jersey, U.S.) 10.14 Bristol-Myers Squibb (New York, U.S.) 10.15 Mylan N.V. (Hertfordshire, U.K.) 10.16 Incyte Corporation (Switzerland) 10.17 Incyte Corporation (Switzerland) 10.18 Novartis AG (Switzerland) 10.19 LEO Pharma A/S (Denmark, Europe) 10.20 Mylan N.V., (Hertfordshire, U.K.) 10.21 Astellas Pharma Inc. (Tokyo, Japan) 10.22 clinuvel pharmaceuticals ltd. (Victoria, Australia) 10.23 Dr. Reddy’s Laboratories Ltd. (India) 10.24 Glenmark Pharmaceuticals Ltd. (India) 10.25 Panacea Biotec Ltd. (India) 10.26 Strides Pharma (India) 10.27 Science Limited (Japan) 10.28 Astellas Pharma Inc. (Tokyo, Japan) 10.29 Aurobindo Pharma Ltd. (India) 10.30 Teva Pharmaceutical Industries Ltd. (Israel)

About This Report

Report ID 168196
Category Healthcare
Published Date Dec 2022
Updated Date
Contact Us